Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 14, 2025 16:05 ET | Source: Alumis Inc.

Alumis Reports First Quarter 2025 Financial Results and Highlights Recent Achievements

Alumis Reports First Quarter 2025 Financial Results and Highlights Recent Achievements
May 13, 2025 13:00 ET | Source: Alumis Inc.

Alumis Stockholders Approve Merger with ACELYRIN

Alumis Stockholders Approve Merger with ACELYRIN
April 21, 2025 06:30 ET | Source: Alumis Inc.

Alumis and ACELYRIN Announce Amended Merger Agreement

Alumis and ACELYRIN Announce Amended Merger Agreement
April 04, 2025 16:34 ET | Source: Alumis Inc.; ACELYRIN, INC.

Alumis and ACELYRIN File Joint Definitive Proxy Statement for Proposed Merger

Alumis and ACELYRIN file joint definitive proxy statement for proposed merger, expected to close in 2Q 2025
March 25, 2025 02:30 ET | Source: Alumis Inc.

Alumis and Kaken Pharmaceutical Announce Collaboration and Licensing Agreement for ESK-001 in Dermatology in Japan

Alumis and Kaken Pharmaceutical collaborate for oral next-generation TYK2 inhibitor ESK-001 in dermatology in Japan
March 19, 2025 16:05 ET | Source: Alumis Inc.

Alumis Reports Year End 2024 Financial Results and Highlights Recent Achievements

Alumis Reports Year End 2024 Financial Results and Highlights Recent Achievements
March 10, 2025 08:00 ET | Source: Alumis Inc.

Alumis to Present at Leerink's 2025 Global Healthcare Conference

Alumis to Present at Leerink's 2025 Global Healthcare Conference
March 08, 2025 09:00 ET | Source: Alumis Inc.

Late-Breaking ESK-001 Phase 2 OLE Data Presented at 2025 AAD Annual Meeting Demonstrate Robust Clinical Responses Over 52-Weeks in Psoriasis

ESK-001 demonstrated robust clinical responses and was well tolerated over 52 weeks in a Phase 2 clinical trial, presented in a late-breaker at AAD 2025
March 04, 2025 09:01 ET | Source: Alumis Inc.

Alumis and ACELYRIN Reaffirm Strategic and Financial Rationale of Proposed Merger

Alumis and ACELYRIN Reaffirm Strategic and Financial Rationale of Proposed Merger
February 28, 2025 09:08 ET | Source: Alumis Inc.

Alumis Announces Late-Breaker Psoriasis Presentation of 52-week Phase 2 OLE Data for ESK-001 at 2025 American Academy of Dermatology Annual Meeting and Accelerated Topline Phase 3 Data Readout

Alumis to Present Late-Breaker Psoriasis 52-Week Phase 2 Data Data for ESK-001 at AAD, Data from Ongoing Phase 3 in 1Q 2026

Next Page keyboard_arrow_right